ClinicalTrials.gg
RecruitingNCT06289712EVALHEPUpdated Mar 4, 2024

Evaluation of the Ablation of Hepatic Lesions by Electroporation

An observational study in Liver Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.

Planned enrollment
24th of 26
50 · median 303
Started
2023
with 5 others
Observational
26 of 93
11 open now
Primary completion
2025-05
later than 4 of 27 live
Registered
85th of 93
by date
Lead sponsor
9 of 93
Assistance Publique - Hôpitaux de Paris

Among the 93 studies in Liver Neoplasms with a site in France, this one is the 24th largest by planned enrollment of the 26 observational ones that give a count, is one of 6 that started in 2023, is one of 26 observational ones, reaches primary completion later than 4 of the 27 other live ones, and was the 85th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Liver Neoplasms with a site in France, or all of them as a file.
02

Study summary

Irreversible electroporation is a curative treatment for cancerous liver lesions, performed on deep-seated tumors that are not eligible for surgical resection or percutaneous thermal ablation.

The EVALHEP project aims to develop criteria for evaluating the effectiveness of the treatment based on imaging, mathematical models, and numerical simulations to assist radiologists who perform these complex procedures.

Read the detailed description

Percutaneous destruction of malignant liver tumors has been developing in routine clinical practice for around twenty years, and is performed by interventional radiologists under imaging guidance (ultrasound, computed tomography (CT), Cone-Beam CT...).

Irreversible electroporation (IRE) is a percutaneous tumor destruction technique distinguished from other ablation methods by its non-thermal mechanism of action. The rationale behind IRE is that cells subjected to a powerful pulsed electric field will have their membrane irreversibly damaged and destroyed, while the surrounding extracellular matrix will be respected. This technology offers the opportunity to effectively destroy lesions that would be impossible to treat by any other method, due to their critical tumor location, close to vital structures at risk.

Although it has demonstrated its clinical efficacy over the years, with the potential to provide safe, curative treatment for patients with deep, poorly located tumors, IRE is considered a complex procedure, subject to numerous variability factors, and remains under-utilized to this day. Precise insertion of several needles (up to 6) at tumor level is required to obtain a homogeneous electric field of sufficient intensity. To date, there is no way of assessing the effectiveness of the procedure in real time, and inaccuracies in needle positioning or in treatment parameters will generate changes in the distribution of the electric field that may adversely affect treatment efficacy. What's more, it remains difficult to assess treatment efficacy on post-therapy images, the interpretation of which is subject to controversy.

The Interventional Radiology (IR) unit of the University Hospitals of Paris Seine Saint Denis (HUPSSD) has been using IRE for over 10 years as part of its clinical routine, mainly for the ablation of liver tumors, and in particular hepatocellular carcinoma (HCC) which is inoperable and ineligible for conventional thermo-ablation. Over the past ten years, more than 350 patients have benefited from one or more IREs for the treatment of liver tumors at HUPSSD, making the department a reference center in the field.

Thanks to the contributions of mathematics applied to oncology, numerical tools and the clinical experience of the HUPSSD IR department, the aim of this project is to develop evaluation criteria for IRE ablations of liver tumors based on clinical imaging and numerical simulations of the electric field.

03

Conditions studied

  • Liver Cancer

Keywords

  • Liver cancer
  • Hepatocellular Carcinoma
  • Irreversible Electroporation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with liver cancer (hepatocellular carcinoma) treated by IRE between 2022 and 2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Informed patients who have not objected to participating in the research, or in the case of deceased patients, who have not objected to the processing of their data during their lifetime.
  • Diagnosis of malignant liver tumor based on either :

    • Anatomopathological analysis based on an image-guided prior to surgery (or performed during surgery and contributing to the diagnosis).
    • Criteria for non-invasive diagnosis of HCC on pre-procedural imaging: CT and/or MRI with contrast injection demonstrating tumor enhancement kinetics after injection typical of HCC (arterial contrast and portal and/or late lavage of a tumor over 10 mm in the presence of chronic liver disease, EASL criteria) and/or Li-RADS 5 classification.
  • Percutaneous removal of liver tumor by Irreversible Electroporation (IRE) performed during the study period.
  • Complete peri-interventional imaging file including:

    • CT and/or MRI of the liver with contrast injection performed within 3 months prior to the procedure
    • Early liver MRI within 4 days of procedure
    • Post-treatment hepatic MRI performed 3 to 6 weeks after the IRE procedure
  • Cone-Beam CT (CBCT) volume reconstructions acquired during the IRE procedure available and including at least :

    • An initial acquisition before electrode placement
    • An acquisition with the electrodes in place in their final position
  • Per-procedural data recorded in the available IRE generator, including the number of electrodes, their schematic spatial configuration, pulse data with test pulses, applied potential (Volt) and measured currents (Amperes) between each electrode combination.

Exclusion criteria

Exclusion Criteria:

  • to MRI:

    • Implantable cardiac pacemaker or defibrillator not compatible with MRI, neurostimulator, cochlear implant, intra-cerebral ferromagnetic vascular clips, intraocular or cerebral metallic foreign bodies, insulin pump
  • Contraindication to percutaneous IRE treatment due to :

    • the presence of uncontrolled cardiac rhythm disorders
    • Presence of a Pacemaker or implantable cardioverter defibrillator
  • Absence of CBCT volume images of the IRE needles in their final position (or modification of their position between the time of CBCT acquisition and delivery of the electrical impulses).
  • If the tumor treated corresponds to a remnant after another locoregional treatment modality (but inclusion possible if the tumor treated corresponds to a local recurrence if it was discovered more than 4 months after a locoregional treatment deemed complete).
  • Patient under guardianship
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Correlate 3D numerical simulations of the IRE electric field with patient imaging follow-up

    Demonstrate a correlation between the treatment zones segmented on post-therapy MRI scans and the three-dimensional electric field isolines obtained using digital simulations.

    Time frame: 72 hours and 1 month after treatment

Secondary outcomes

  1. Calculation of the tumor coverage rate by the various electric field isolines at different relevant values (for example, three-dimensional isolines between 300 and 700V.cm-1 will be simulated numerically).

    Determine a threshold for IRE of liver tumors by combining numerical electric field resolution and post-treatment imaging data.

    Time frame: 72 hours and 1 month after treatment

  2. Correlation of recovery rate with treatment outcome and local recurrence during clinical follow-up

    Assess inter-individual variations in liver and tumor conductivity values based on impedance data provided by the IRE generator.

    Time frame: 72 hours and 1 month after treatment

  3. Identification and assessment of imaging biomarkers (radiomics-based) using numerical simulation and post-therapeutic imaging for treatment response evaluation.

    Determine a threshold electric field value to be reached for complete treatment (calculation of sensitivity, specificity, PPV, NPV, ROC curve)

    Time frame: 72 hours and 1 month after treatment

  4. Digital resolution of electrical potential and tissue conductivity values from test pulses at the start of the procedure.

    Evaluate the most suitable and clinically relevant numerical electroporation model (linear/non-linear, static/dynamic).

    Time frame: 72 hours and 1 month after treatment

  5. Develop software solutions potentially usable in real-time and tailored for clinical use.

    Demonstrate a correlation between the treatment zones segmented on post-therapy MRI

    Time frame: 72 hours and 1 month after treatment

07

Study locations

1 of 1 sites recruiting
  • Service d'imagerie diagnostique et interventionnelle tri-site des HUPSSD
    Bobigny, 93009, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for May 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 4, 2024
StartActual
Nov 23, 2023
Primary completionEst.
May 23, 2025
CompletionEst.
May 23, 2025
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06289712
Collaborators
Inria Team MONC
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Nov 23, 2023
Primary completion
May 23, 2025 (estimated)
Completion
May 23, 2025 (estimated)
Last update
Mar 4, 2024

Study contacts

Olivier SUTTER, Pr,MD, PhD
Contact
olivier.sutter@aphp.fr
01 72 40 00 12
Clair POIGNARD, Pr,MD, PhD
Contact
clair.poignard@inria.fr
05 40 00 21 27
Olivier SUTTER, Pr,MD, PhD
study director · Assistance Publique de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion